Researchers in Sweden have developed an oral pill that primes muscle metabolism to burn fat and improve blood glucose control, offering an alternative to appetite-suppressing GLP-1 injections by targeting muscle function rather than hunger signals.
The new drug acts through a refined beta-2 agonist designed to stimulate muscle energy use while avoiding the heart overstimulation that plagued earlier compounds. Early results include promising animal work and tolerable safety signals in a small human trial, suggesting the approach deserves further study. Unlike current injectable options, this pill aims to boost metabolic rate rather than simply blunt appetite.
A team from Karolinska Institutet and Stockholm University led the research, testing the compound in both preclinical models and a phase 1 human study that involved healthy volunteers and people with type 2 diabetes. The human trial was small and focused on safety, tolerability, and initial metabolic signals rather than proving long-term benefit. Still, investigators reported the drug controlled blood glucose, favored fat loss and helped preserve muscle in animals, while showing good tolerability in people.
Developers say the compound caused fewer of the common side effects seen with GLP-1s, which are known to produce appetite suppression, nausea and sometimes broader tissue loss. That pattern of fewer gastrointestinal issues and less muscle wasting would be important if it holds up in larger studies. The mode of action makes it a logical candidate to use either on its own or alongside existing therapies to achieve complementary effects.
“Our results point to a future where we can improve metabolic health without losing muscle mass,” said Tore Bengtsson, professor at the Department of Molecular Bioscience at Wenner-Gren Institute, Stockholm University, in the release. “Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy.”
Shane C. Wright, an assistant professor at Karolinska Institutet, described the medication as having potential to be of “great importance” for people living with type 2 diabetes and obesity, emphasizing the convenience of an oral route. “Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections,” he added. Oral therapies can lower barriers to treatment for patients who dislike or cannot manage injections.
Independent commentators urged caution despite the encouraging signals, pointing out that phase 1 data are inherently limited. “This compound’s mechanism of action could address some specific metabolic concerns with previous weight reduction therapies, such as the loss of both muscle and fat tissue,” Wickham told Fox News Digital. He noted that larger, longer trials are essential to evaluate safety and real-world effectiveness over months and years.
The researchers themselves flagged limitations in translating mouse outcomes to human disease, noting the complexity of obesity and diabetes in people compared with controlled lab models. Structural biology work is still needed to pinpoint how the drug interacts with its target, and the team acknowledged that “Our phase 1 data show that compound 15 is well-tolerated; however, conclusive clinical efficacy data (on how the drug controls glucose metabolism) are currently still lacking.” That candor underscores the early stage of development.
Plans are in place for a larger phase 2 study to test efficacy in a broader and more diverse group, including individuals with obesity, and to monitor outcomes over a longer period. The effort so far has drawn funding from national and charitable sources and included collaborations with multiple universities. If later trials confirm safety and metabolic benefits without muscle loss, the drug could become a useful tool alongside existing options.
The concept of improving metabolism by boosting muscle energy use rather than suppressing appetite flips the current popular paradigm and opens new therapeutic possibilities. Success will depend on showing consistent, durable benefits and an acceptable safety profile in larger populations. For now, the work represents an intriguing early step toward treatments that protect muscle while tackling excess fat and blood glucose control.
